Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

Inclusion Criteria:

- Men and women aged 18 years and older. The lower age limit may be higher if legally
required in the participating country

- Women of childbearing potential can only be included in the study if a pregnancy test
is negative and if they agree to use adequate contraception when sexually active

- Subjects with worsening chronic heart failure requiring emergency presentation to
hospital and treatment with intravenous diuretics at hospital

- Subjects with clinical diagnosis of chronic heart failure (CHF) either ischemic or
non ischemic, New York Heart Association (NYHA) functional class II-IV

- Subjects with type 2 diabetes mellitus and / or

- Subjects with 30 mL/min/1.73m2 Diet in Renal Disease Study Group) at screening

- Left ventricular ejection fraction (LVEF)
- Blood potassium
- Systolic blood pressure >/= 90 mmHg without signs and symptoms of hypotension at the
screening visit

Exclusion Criteria:

- Acute de-novo heart failure or acute inflammatory heart disease, e.g. acute
myocarditis

- Acute coronary syndrome (ACS) in last 30 days prior to screening

- Cardiogenic shock

- Valvular heart disease requiring surgical intervention during the course of the study

- Stroke or transient ischemic cerebral attack in the last 3 months prior to the
screening visit

- Concomitant treatment with any mineralocorticoid receptor antagonist (MRA), renin
inhibitor, or potassium-sparing diuretic